CJC Ipamorelin

CJC-1295 and Ipamorelin are a commonly paired peptide combination studied for their role in growth hormone–releasing signaling pathways. Together, they are designed to support endogenous growth hormone pulsatility by stimulating natural release mechanisms rather than supplying exogenous hormone.
 
CJC-1295 is a growth hormone–releasing hormone (GHRH) analogue studied for its ability to extend the duration and amplitude of growth hormone signaling, while Ipamorelin is a selective growth hormone secretagogue studied for its targeted receptor activity and minimal impact on cortisol or prolactin pathways in research settings.
 
This combination has been explored in research contexts focused on recovery, body composition signaling, sleep-related hormone rhythms, and metabolic support, without engaging direct growth hormone administration.
 
This product is supplied in lyophilized form and is intended for research and professional use only, under appropriate clinical oversight.
 
Key Characteristics:
 
Dual-peptide combination targeting growth hormone release pathways
Designed to support natural pulsatile hormone signaling
Studied for recovery, metabolic signaling, and sleep-related hormone rhythms
Does not supply exogenous growth hormone
Supplied in lyophilized form
 
Important Notice:
This product is not intended to diagnose, treat, cure, or prevent any disease. Intended for use by qualified professionals in accordance with applicable regulations.